Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of fosamprenavir-based salvage regimens in protease inhibitor-experienced adults with HIV virological failure
2004-003827-10Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir, lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by GSK. Primary endpoint: Average area under the curve minus baseline in plasma HIV-1 RNA at Week 24. Started Nov 2004; status: completed.
02
Drugs
fosamprenavirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-003827-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003827-10.